Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model

The oncolytic reovirus (RV) has demonstrated clinical efficacy and minimal toxicity in a variety of cancers, including multiple myeloma (MM). MM is a malignancy of plasma cells that is considered treatable but incurable because of the 90% relapse rate that is primarily from drug resistance. The syst...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Thirukkumaran, Chandini M., Shi, Zhong Qiao, Nuovo, Gerard J., Luider, Joanne, Kopciuk, Karen A., Dong, Yuan, Mostafa, Ahmed A., Thakur, Satbir, Gratton, Kathy, Yang, Ailian, Chin, Alex C., Coffey, Matt C., Jimenez-Zepeda, Victor H., Stewart, Douglas, Chesi, Marta, Bergsagel, P. Leif, Morris, Don
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6418503/
https://ncbi.nlm.nih.gov/pubmed/30850386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018025593
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados